Adamas Pharmaceuticals Inc.

(ADMS) Trade

By |

Profile

Adamas Pharmaceuticals Inc is a pharmaceutical company focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems. The company has developed and got approved the drug GOCOVRI.

Contact Information

Website: www.adamaspharma.com
Email: ir@adamaspharma.com
Main Phone: +1 510 450-3500
Address: 1900 Powell Street
Address 2: Suite 750
State: CA
City / Town: Emeryville
Country: USA
Postal Code: 94608

Issuer Information

Exchange: NSD
CEO: Gregory Went
Employees: 153
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 19.55 $ 0.42 (2.20%)
Last Price 19.55 Change $ 0.42 Change % 2.20 Tick N/A
Bid 19.52 Bid Size 200.00 Ask 19.57 Ask Size 100.00
Open 19.27 High 19.72 Low 19.00 Prev Close 19.13
Last Trade Volume 209,286 52 Wk Hi 44.00 52 Wk Low 17.68
Market Cap 531.6 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 27,190,453.00 EPS (TTM) -4.93 PE Ratio N/A Exchange NSD
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 18
Number of Buys 0 9
Number of Sells 4 9
Net Activity -7342 -297198
Last 10 Buys Shares
Jonathan Feiber 1,000
William W. Ericson 1,000
Jonathan Feiber 1,000
William W. Ericson 1,000
Jonathan Feiber 1,000
William W. Ericson 1,000
William W. Ericson 1,000
Jonathan Feiber 1,000
Jonathan Feiber 1,000
William W. Ericson 1,000
Last 10 Sell Shares
Gregory Went 1,000
Jennifer J. Rhodes 1,000
Christopher B. Prentiss 1,000
Rajiv Patni 1,000
Jennifer J. Rhodes 1,000
Jay R Jeffrey 1,000
Jennifer J. Rhodes 1,000
Jay R Jeffrey 1,000
Jay R Jeffrey 1,000
Rajiv Patni 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 70 70 70 70
Low Target Price Estimate 34 34 34 34
Mean Target Price Estimate 48.14 48.13 48.13 48.14
Standard Deviation 13.21 12.23 12.23 13.21
Date of Most Recent Estimate 05/04/18 05/04/18 05/04/18 05/04/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 9 9 9 8
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1